RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
A panel of outside advisers to the U.S. Food and Drug Administration voted that one of two large studies on Biogen Inc.’s experimental Alzheimer’s disease drug cannot be viewed alone without regard for the other failed trial.
A study published in the Journal of the American Medical Association shows that a new blood test may be helpful for detecting Alzheimer’s disease as early as 20 years before the onset of cognitive impairment.
Denali Therapeutics and development partner Sanofi announced data from the Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). After apparent disappointing results, the companies have chosen to pause the studies with the drug and shift their resources to a similar drug, DNL788, for the same indications.
Little headway has been made in developing a treatment for Alzheimer’s disease, but that could be changing.
Biogen reported full-year 2019 financial results, citing total revenues of $14.378 billion, an increase of 7% from the previous year.
Novo Nordisk is involved in a clinical trial using the company’s GLP-1 analog diabetes drug Victoza to evaluate if the medicine can improve brain function and cognition in Alzheimer’s patients.
In August 1963, the Rev. Martin Luther King delivered his famous “I Have a Dream” speech that called for equality among all people, regardless of their ethnicity, as well as a vision for a better America for all. While the noble dreams that King outlined on that hot day in Washington, D.C. so many years ago have unfortunately not yet been fully realized, there are other kinds of dreams that may be closer to being achieved, particularly in the area of new medications for serious diseases.
Biogen Inc. agreed to buy an early-stage experimental treatment from Pfizer Inc. to test in patients with Alzheimer’s and Parkinson’s disease.
Biogen is discontinuing development of an experimental therapy for a rare brain disease after the treatment failed a mid-stage trial, the latest setback in attempts to develop a medicine for the disorder.